Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy dkoding.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dkoding.in Daily Mail and Mail on Sunday newspapers.
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, January 9, 2023 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that the
Investegate announcements from Santhera Pharmaceuticals Holdi, European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, October 31, 2022 - Santhera Pharmaceuticals (SIX: SANN) announces that the European Medicines Agency (EMA) has validated its marketing authorization application (MAA) for vamorolone
FDA receives Santhera and ReveraGen s application for Duchenne muscular dystrophy treatment pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.